Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19327277 | 0.93 | ATM (0.47) | ATMLMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19327278 | 0.93 | ATM (0.47) | ATMLMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL19327330 | 0.85 | LMNA (0.50) | ATMLMNASMN1; SMN2NPSR1DRD2 | |
| SCHEMBL19327265 | 0.85 | RAB9A (0.45) | ATMLMNASMN1; SMN2NPSR1DRD2 | |
| SCHEMBL19327329 | 0.85 | LMNA (0.50) | ATMLMNASMN1; SMN2NPSR1DRD2 | |
| SCHEMBL19327321 | 0.85 | ATM (0.47) | ATMLMNANPSR1DRD2DRD3 | |
| SCHEMBL19327267 | 0.85 | RAB9A (0.45) | ATMLMNASMN1; SMN2NPSR1DRD2 | |
| SCHEMBL19327322 | 0.85 | ATM (0.47) | ATMLMNANPSR1DRD2DRD3 | |
| SCHEMBL19327316 | 0.84 | ATM (0.50) | ATMDRD2MEN1KMT2AOPRM1 | |
| SCHEMBL19327318 | 0.84 | ATM (0.50) | ATMDRD2MEN1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124503-B2 | Compositions and methods for acylating lactams | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124503-B2 | Compositions and methods for acylating lactams | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-09-21 | — | — | US | disclosed |
| US-20190077796-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-03-14 | — | — | US | disclosed |
| US-20190077796-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-03-14 | — | — | US | disclosed |
| US-10040784-B2 | Compositions and methods for acylating lactams | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040784-B2 | Compositions and methods for acylating lactams | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040784-B2 | Compositions and methods for acylating lactams | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170260172-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-09-14 | — | — | US | disclosed |
| US-20170260172-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-09-14 | — | — | US | disclosed |
| US-20170260172-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124503-B2 | Compositions and methods for acylating lactams | COASY, ASNS, NAAA | ATM 3327/4885LMNA 2445/4885SMN1; SMN2 2602/4885 |
| US-20170260172-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | COASY, NAAA, ASNS | ATM 2679/4885LMNA 2930/4885SMN1; SMN2 2690/4885 |
| US-10040784-B2 | Compositions and methods for acylating lactams | COASY, NAAA, ASNS | ATM 2679/4885LMNA 2930/4885SMN1; SMN2 2690/4885 |
| US-20190077796-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | COASY, NAAA, ASNS | ATM 2679/4885LMNA 2930/4885SMN1; SMN2 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.